Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grown Rogue InternationalGRUSF 39 Debt-to-Equity is 1.79 as of Jun. 2026, which is 209% above its 10-year median of 0.58. GuruFocus rates GRUSF with a GF Score™ of 39/100 and a GF Value™ of $0.57 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 813 Drug Manufacturers companies, Grown Rogue International ranks worse than 92.87% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Grown Rogue International's Debt-to-Equity or its related term are showing as below:
GRUSF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -3.73 Med: 0.58 Max: 1.79
Current: 1.79
During the past 13 years, the highest Debt-to-Equity Ratio of Grown Rogue International was 1.79. The lowest was -3.73. And the median was 0.58.
GRUSF's Debt-to-Equity is ranked worse than 92.87% of 813
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs GRUSF: 1.79
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Grown Rogue International Debt-to-Equity Related Terms
Grown Rogue International Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Grown Rogue International's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grown Rogue International Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grown Rogue International's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Grown Rogue International's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grown Rogue International (GRUSF) has a Debt-to-Equity of 1.79 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Grown Rogue International and its competitors. This is 209% above median its historical median of 0.58. According to the industry distribution chart, Grown Rogue International ranks #755 out of 813 companies in the Drug Manufacturers industry, placing it in the top 92.9%.
Is Grown Rogue International's Debt-to-Equity too high?
Grown Rogue International's current Debt-to-Equity of 1.79 is 209% above median its 10-year median of 0.58. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Grown Rogue International's value of 1.79 is 563% above this industry median. Based on the distribution chart, Grown Rogue International ranks #755 out of 813 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Grown Rogue International has a GF Score™ of 39/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grown Rogue International's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Grown Rogue International ranks #755 out of 813 companies for Debt-to-Equity. This places Grown Rogue International in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Grown Rogue International's value of 1.79 is 563% above this benchmark. While the company's 10-year median is 0.58 vs. the industry median of 0.27, Grown Rogue International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grown Rogue International's current Debt-to-Equity of 1.79 is 563% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Grown Rogue International and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grown Rogue International's current Debt-to-Equity is 1.79, which is 209% above median its own 10-year median of 0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grown Rogue International stock overvalued right now?
Based on GuruFocus' analysis, Grown Rogue International (GRUSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.57, compared to a current price of $0.43 — trading 24.6% below its estimated fair value. The current Debt-to-Equity is 1.79, which is 209% above median its 10-year median of 0.58 and 563% above the Drug Manufacturers industry median of 0.27. Grown Rogue International's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Grown Rogue International (GRUSF), the current Debt-to-Equity is 1.79 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grown Rogue International (GRUSF) Overvalued in 2026?
Based on GuruFocus' analysis, Grown Rogue International stock appears to be undervalued.
The current stock price of $0.43 is trading 24.6% below its estimated GF Value™ of $0.57.
GuruFocus considers Grown Rogue International to be Modestly Undervalued.
Key valuation signals for GRUSF:
Debt-to-Equity: 1.79 (209% above median its 10-year median of 0.58)
GF Value™: $0.57 vs. price of $0.43 (24.6% below fair value)
Industry Position: 563% above the Drug Manufacturers median (#755 of 813)
No single metric tells the full story. See the GRUSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grown Rogue International Inc is engaged in the business of growing and selling cannabis products. Its primary cannabis product produced and sold is cannabis flower. Geographically, the company generates a majority of its revenue from the United States. The company has identified three operating segments: the Oregon segment represents cannabis production and sales activities in Oregon; the Michigan segment represents cannabis production and sales activities in Michigan; and the New Jersey segment represents cannabis production and sales activities in New Jersey.
39GF Score
Get the complete analysis for GRUSF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRUSF has been successfully added to your 
